Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in preclinical study
On Jul. 28, 2021, GlaxoSmithKline and Vir Biotechnology announced they had signed a Joint Procurement Agreement with the…